Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1273-1283

  Huang, Li ^a   Chen, Wei ^a   Liang, Peiwen ^a   Hu, Wenjie ^a   Zhang, Kunsong ^a   Shen, Shunli ^a   Chen, Jiancong ^a   Zhang, Zhaohui ^a   Chen, Bin ^a   Han, Yuyan ^b   Meng, Fanyin ^c,d   DeMorrow, Sharon ^c,d   Yin, Xiaoyu ^a   Lai, Jiaming ^a   Liang, Lijian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Biliary tract cancers; Biomarker; CYFRA 21 1; Diagnosis; Prognosis

Indexed keywords

ANTIGEN CYFRA21.1; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BILE DUCT NEOPLASMS; BLOOD; CANCER STAGING; CHI SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; GALLBLADDER NEOPLASMS; HUMAN; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHI-SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-19; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84931042185     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3472-0     Document Type: Article

References (31)

1. Hezel AF, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531–3540.
2. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–1229.
3. Liu LN, Xu HX, Lu MD, et al. Contrast-enhanced ultrasound in the diagnosis of gallbladder diseases a multi-center experience. PLoS ONE. 2012;7:e48371.
4. Alvaro D. Serum and bile biomarker for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–284.
5. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.
6. Stieber P, Bodenmüller H, Banauch D, et al. Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem. 1993;26:301–304.
7. Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer. 1994;30A:601–606.
8. Kashihara T, Ohki A, Kobayashi T, et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J Gastroenterol. 1998;33:447–453.
9. Uenishi T, Kubo S, Hirohashi K, et al. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer. 2003;88:1894–1899.
10. Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:583–589.
11. Chapman MH, Sandanayake NS, Andreola F, et al. Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. J Clin Exp Hepatol. 2011;1:6–12.
12. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, eds. AJCC Cancer Staging Manual. 2010.
13. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–35.
14. Wu JC, Martin AF, Raghu NK. Measures, uncertainties, and significance test in operational ROC analysis. J Res Natl Inst Stand Technol. 2011;116:517–537.
15. Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34:219–228.
16. Schweizer J, Bowden PE, Coulombe PA, et al. New consensus nomenclature for mammalian keratins. J Cell Biol. 2006;174:169–174.
17. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167–1175.
18. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94:851–857.
19. Ding SJ, Li Y, Tan YX, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004;3:73–81.
20. Uenishi T, Yamazaki O, Yamamoto T, et al. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2006;13:239–244.
21. Dohmoto K, Hojo S, Fujita J, et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer. 2001;91:468–473.
22. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30:127–138.
23. Alix-Panabières C, Vendrell JP, Slijper M, et al. Full-length cytokeratin-19 is released by human tumor cells a potential role in metastatic progression of breast cancer. Breast Cancer Res. 2009;11:R39.
24. Fuks D, Regimbeau JM, Le Treut YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 study group. World J Surg. 2011;35:1887–1897.
25. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–1700.
26. Brabon AC, Williams JF, Cardiff RD. A monoclonal antibody to a human breast tumor protein released in response to estrogen. Cancer Res. 1984;44:2704–2710.
27. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg. 2008;248:273–279.
28. Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg. 2010;251:675–681.
29. Li SQ, Liang LJ, Hua YP, et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl). 2010;122:2286–2291.
30. Pilgrim CH, Groeschl RT, Turaga KK, Gamblin TC. Key factors influencing prognosis in relation to gallbladder cancer. Dig Dis Sci. 2013;58:2455–2462.
31. Jensen LH. Biliary-tract cancer: improving therapy by adding molecularly targeted agents. Lancet Oncol. 2012;13:118–119.